Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | FABP1 | P07148 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | LIFR | P42702 | 1/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354246 | 0.87 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 0.87 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996233 | 0.87 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29459634 | 0.87 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL24212693 | 0.85 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3640492 | 0.83 | NR1H4 (0.75) | NR1H4LIFRHSD17B13 | |
| SCHEMBL14601398 | 0.83 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16448984 | 0.82 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL30080606 | 0.82 | NR1H4 (0.74) | NR1H4LIFRHSD17B13 | |
| SCHEMBL3641386 | 0.81 | NR1H4 (0.75) | NR1H4LIFRHSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191100-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040860-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-3399991-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-3349751-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018039521-A1 | DEUTERATED CENICRIVIROC | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-3191100-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2017120546-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017048322-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016040860-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |